Treatment of AL-amyloidosis - Results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis;Léčba AL-amyloidózy - Výsledky jednoho pracoviště a přehled publikovaných zkušeností s novými léky (bortezomibem, thalidomidem a lenalidomidem) u AL-amyloidózy

Vnitrni Lekarstvi

Volumn 56, Issue 3, 2010, Pages 190-209

  Adam, Zdeněk ^a   Pour, L ^a   Krejci M ^a   Zahradova L ^a   Krivanova A ^a   Smardova J ^a   Kovarova L ^a   Stepankova S ^a   Moulis, M ^a   Kren L ^a   Vesely K ^b   Svobodova I ^b   Cermakova Z ^c   Nedbalkova M ^a   Mayer, J ^a   Hajek R ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c Oddeleni Klinicke Biochemie   (Czech Republic)

Author keywords

Al amyloidosis; Bortezomib; Cardiomyopathy; Coagulopathy; High dose chemotherapy and autologous transplantation; Light chain deposition disease; Monoclonal gammopathy; Nephrotic syndrome; Neuropathy; Thalidomide

Indexed keywords

ALKYLATING AGENT; AMYLOID PROTEIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; PARAPROTEIN; PREDNISONE; THALIDOMIDE; VINCRISTINE; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; AL AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; AUTOTRANSPLANTATION; BLOOD CLOTTING DISORDER; CARDIOMYOPATHY; CLINICAL ARTICLE; CONSTIPATION; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOMA; HEPATOSPLENOMEGALY; HUMAN; KIDNEY FAILURE; LIGHT CHAIN; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NEUROPATHY; PATIENT ASSESSMENT; PROTEIN CONTENT; REMISSION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG COMBINATION; MIDDLE AGED; REVIEW;

ADULT; AGED; AMYLOIDOSIS; BORONIC ACIDS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZINES; THALIDOMIDE;

EID: 77951008836     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596.
2. Sideras K, Gertz MA. Amyloidosis. Adv Clin Chem 2009; 47: 1-44.
3. Lavatelli F, Perlman DH, Spencer B. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008; 7: 1570-1583.
4. Anesi E, Palladini G, Perfetti V et al. Therapeutic advances demand accurate typing of amyloid deposits. Am J Med 2001; 111: 243-244. (Pubitemid 32786958)
5. Vrana JA, Zeldenrust SR, Theis JD et al. Diagnosis and classification of amyloidosis in abdominal subcutaneous fat specimens using mass spectrometry based proteomics. Blood 2008; 112: 937. Abstract 2710.
6. Lachmann HJ, Booth DR, Booth SE et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2000; 346: 1786-1791.
7. Abraham RS, Geyer SM, Price-Troska TL et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome of light chain-associated amyloidosis (AL). Blood 2003; 101: 3801-3808.
8. Comenzo RL, Zhang Y, Martinez C et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001; 98: 714-720.
9. Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Curr Opin Struct Biol 2008; 18: 771-779.
10. Ščudla V, Pika T. Současné možnosti léčby systémové AL amyloidózy. Vnitř Lék 2009; 55 (Suppl 1): S77-S87.
11. Adam Z, Ščudla V. Klinické projevy a diagnostika AL-amyloidózy a některých dalších typü amyloidóz. Vnitř Lék 2001; 47: 36-45.
12. Tichý M. Primární amyloidóza. Lék Zpr LF UK Hradec Králové 1999; 44: 99-107.
13. Kroupa R, Dastych M, Šenkyřík M et al. Systémová amyloidóza s dominující klinickou manifestací v trávicím traktu. Vnitř Lék 2005; 51: 588-592.
14. Ryšavá R. Amyloidóza ledvin. Postgrad Med 2006; 8: 207-212.
15. Ryšavá R. Léčba paraproteinemické nefropatie a primární amyloidózy ledvin. Aktual v Nefrol 2005; 11: 62-65.
16. Linhartová K, Daum O. Srdeční amyloidóza. Cor Vasa 2005; 47: 328.
17. Kyle RA, Linos A, Beard CM et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County Minnesota, 1950 through 1989. Blood 1992; 79: 1817-1822.
18. Magy-Bertrand N, Dupond JL, Mauny F et al. Incidence of amyloidosis over 3 years. The AMYPRO study. Clin Exp Rhematol 2008; 26: 1074-1078.
19. Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol 2008; 19 (Suppl 4): iv63-iv66.
20. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520-2530.
21. van Gameren II, van Rijswijk MH, Bijzet J et al. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009; 94: 1094-1100.
22. Štraub J, Adam, Z, Gregora E et al. Mnohočetný myelom - projekt časné diagnostiky CRAB. Zdravotnické noviny - Lékařské listy 2007; 16: 4-5.
23. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myelom and releated disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003; 121: 749-757.
24. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
25. Gertz MA, Comenzo R, Falk RH. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
26. Obici L, Perfetti V, Palladini G et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11-22.
27. Palladini G, Campana C, Klersy C et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445.
28. Dispenzieri A, Gertz MA, Kyle RA et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757. (Pubitemid 41095215)
29. Palladini G, Russo P, Lavatelli F. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009; 88: 347-350.
30. Oh IY, Kim HK, Kim YJ et al. An intriguing case of primary amyloidosis with cardiac involvement: symptomatic and echocardiographic improvement with thalidomide treatment. Int J Cardiol 2006; 113: 141-143.
31. Bird J. Guidelines in the diagnosis and management of AL amyloidosis. Brit J Haematol 2004; 125: 681-700.
32. Dispenzieri A, Lacy MQ, Katzmann JA et al Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378-3383.
33. Kumar S, Gertz MA, Lacy MQ et al. Changes in serum free light chain rather then intact monoclonal imunoglobin levels predict outcome with therapyin patients with light chain amyloidosis. Blood 2009; 114 (Suppl N22): 311. Abstract 747.
34. Lachmann HJ, Gallimore R, Gillmore JD et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84. (Pubitemid 36819341)
35. Palladini G, Lavatelli F, Russo P et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis. Blood 2006; 107: 3854-3858. (Pubitemid 43726787)
36. Ščudla V, Minařík J, Schneiderka P et al. Význam sérových hladin volných lehkých řetězců imunoglobulinu v diagnostice a hodnocení aktivity mnohočetného myelomu a vybraných monoklonálních gamapatií. Vnitř Lék 2005; 51: 1249-1259.
37. Waldenström H. On the formation and disappearance of amyloid in man. Acta Chir Scand 1928; 63: 479-530.
38. Wechalekar AD, Merlini G, Gillmore JD et al. Role of NT-ProBNP to assess the adequacy of treatment response in AL amyloidosis. Blood 2008; 112: 596-759.
39. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207.
40. Gertz MA, Kyla RA, Greip PP. Response rates, and survival in primary systemic amyloidosis. Blood 1991; 77: 257-262.
41. Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17: 262-267.
42. Dhodapkar MV, Hussein MA, Rasmussen E et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520-3526.
43. Palladini G, Perfetti V, Obici L et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938. (Pubitemid 38451663)
44. Goodmann H, Lachmann H, Bradsell AR et al. Intermediate dose melpahalan and dexamethasone treatment in 144 patients with systemic AL-amyloidosis. Blood 2004; 104: 755-759.
45. Goodman H, Wechalekar A, Lachmann H et al. Clonal disease response and clinical outcome in 229 patients with AL-amyloidosis treated with VAD-like chemotherapy. Hematologica 2008; 90: 201-203.
46. Palladini G, Anesi E, Perfetti V et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001; 113: 1044-1046. (Pubitemid 32634774)
47. Palladini G, Russo P, Nuvolone M et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110: 787-788. (Pubitemid 47105419)
48. Palladini G, Russo P, Foli A et al. Treatment with oral melphalan and dexamethasone in an extended population with AL amyloidosis. Blood 2009; 114 (Suppl N22): 1496. Abstract 3889.
49. Sanchorawala V, Seldin DC, Sloan JM et al. Oral cyclic melphalan and dexametasone treatment in the treatment of patients with high dose amyloidosis, ineligible for high dose melphalan and stem cell transplantation. Blood 2009; 114 (Suppl N22): 748. Abstract 1883.
50. Dispenzieri A, Lacy MQ, Rajkumar SV et al. Poor tolerance to high dose thalidomide in patients with light chain associated (AL) amyloidosis. Amyloid 2003; 10: 257-261.
51. Dispenzieri A, Lacy MQ, Geyer SM et al. Low dose single agent thalidomide is tolerated in patients with primary amyloidosis, but responses are limited. Blood 2004; 104. Abstract 4920.
52. Palladinini G, Perfetti V, Perlini S et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949-2951. (Pubitemid 40446290)
53. Wechalekar AD, Goodman HJ, Lachmann HJ et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457-464.
54. Gibbs SDJ, Sattianayagam PT, Lachmann H et al. Risk adapted cyclophosphamide, thalidomide and dexamethasone (CTD) for treatment of systemic AL-amyloidosis: long term outcome of 202 Patients. Blood 2008; 112: 611. Abstract 1733.
55. Gibbs SD, Gillmore J, Satttianayagam PT et al. AL-amyloidosis both oral melphalan and dexametzasone and risk adapted cyclophosphamide, thalidomide, and dexamethasone (CTD) have similar efficacy as upfront treatment. Blood 2009; 114 (Suppl N22): 310. Abstract 745.
56. Gillmore J, Cocks K, Gibbs DJB et al. Cyclophosphamide, thalidomide and dexamethasone (CTD) versus melphalan and dexamethasone (MD) for newly diagnosed systemic AL amyloidosis. Result from the UK amyloidosis treatment trial. Blood 2009; 114 (Suppl N22): 1120. Abstract 2869.
57. Seldin DC, Choufani EB, Dember LM et al. Tolerability and efficacy of thalidomide for the treatment of light chain associated (AL) amyloidosis. Clin Lymphoma 2003; 3: 241-246.
58. Cohen AD, Zhou P, Chou J et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007; 139: 224-233. (Pubitemid 47495869)
59. Kastritis E, Anagnostopoulos A, Rousnou M et al. Treatment of light chain deposition disease with the combination of bortezomibe and dexamethasone. Blood 2007; 110 (Suppl N11 ). Abstract 64.
60. Kastritis E, Anagnostopoulos A, Roussou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351-1358.
61. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007; 92: 1302-1307.
62. Reece D, Hegenbart U, Merlini G et al. Weekly and twice-weekly bortezomib in patients with systemic AL-amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489-1497.
63. Wechalekar AD, Lachmann HJ, Offer M et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295-298. (Pubitemid 351397721)
64. Kastritis E, Wechalekar AD, Dimopoulos C et al. Significant activity of bortezomib-based therapy in patients with primary systemic AL-amyloidosis. Blood 2008; 112: 321. Abstract 869.
65. Zonder JA, Sanchorawala V, Snyder RM et al. Melphalan, dexamethosone plus bortezomib induces hematologic and organ response in AL-amylolidosis with tolerable neurotoxicity. Blood 2009; 114 (Suppl N22): 310. Abstract 746.
66. Jimenez-Zepeda VH, Reeder CB, Mikhael JR et al. Cyclophophamide, bortezomib and dexamethasone induces rapid and complete response in patients with amyloidosis non eligible for peripheral stem cell transplant. Blood 2009; 114 (Suppl N22): 737. Abstract 1857.
67. Singh V, Saad A, Palmer J et al. Response to bortezomib based induction therapy in newly diagnosed light chain (AL) amyloidosis. Blood 2009; 114 (Suppl N22): 740. Abstract 1867.
68. Lamm W, Willenbacher W, Zojer N et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Blood 2009; 114 (Suppl N22): 1121. Abstract 2871.
69. Sanchorawala V, Wright DG, Rosenzweig M et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492-496.
70. Dispenzieri A, Lacy MQ, Zeldenrust S et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465-470. (Pubitemid 46105939)
71. Dispenzieri L, Lacy M, Zeldenrust SR et al. Long term follow up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone. Blood 2008; 112: 612. Abstract 1737.
72. Kastritis E, Zahoura F, Rousnou M et al. Phase I/II study of lenalidomid, intermediate dose of dexamethasone and low dose cyclophosphamide for the treatment of AL-amyloidosis. Blood 2008; 112: 611. Abstract 1734.
73. Schoenland SO, Bochler T, Ditrich S et al. Single center experience of lenalidomide/dexametazone treatment in 40 patients with light chain amyloidosis. High toxicity in patients with impaired renal and cardiac function. Blood 2008; 112: 612. Abstract 1736.
74. Moreau P, Jaccard A, Benboubker L et al. Lenalidomide with melphalan and dexamethasone in patients with newly diagnosed light chain amyloidosis. A multicenter phase I/II dose escalation study. Blood 2009; 114 (Suppl N22): 177. Abstract 427.
75. Kastritis E, Roussou M, Migkou M et al. A phase I/II study of lenalidomide with low dose dexamethasone and cyclophosphamide for patients with primary systemic light chain amyloidosis. Blood 2009; 114 (Suppl N22): 177. Abstract 428.
76. Sloan JM, Sanchowarala V, Girnius S et al. Melphalan, lenalidomide and dexamethasone combination therapy in patients with AL amyloidosis. Blood 2009; 114 (Suppl N22): 737. Abstract 1859.
77. Palladini G, Russo P, Bragotti LZ et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL-amyloidosis. Blood 2009; 114 (Suppl N22): 1117. Abstract 2863.
78. Kumar S, Hayman SR, Buaudi F et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone in patients with light chain amyloidosis. Blood 2009; 114 (Suppl N22): 1482. Abstract 3853.
79. Sanchorawala V, Skinner M, Quillen K et al. Long-term outcome of patients with AL amyloidosis treated with melphalan and stem cell transplantation. Blood 2007; 110: 3561-3563. (Pubitemid 350159622)
80. Gertz MA, Lacy MQ, Dispenzieri A et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007; 92: 1415-1418.
81. Vesole DH, Perez WS, Akasheh M et al. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006; 81: 880-888. (Pubitemid 43993479)
82. Dispenzieri A, Gertz MA, Kyle RA et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887. (Pubitemid 39202301)
83. Dispenzieri A, Kyle RA, Gertz MA et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787-1789. (Pubitemid 36638428)
84. Gertz MA, Lacy M, Dispenzieri A et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49: 36-41. (Pubitemid 351146880)
85. Skinner M, Sanchorawala V, Seldin DC et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85-93. (Pubitemid 38095403)
86. Yagi S, Akaike M, Ozaki S et al. Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL-cardiac amyloidosis. Intern Med 2007; 46: 1705-1710. (Pubitemid 350111142)
87. Perfetti V, Siena S, Palladini G et al. Long-term results of risk adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary AL amyloidosis. Hematologica 2006; 91: 1635-1643. (Pubitemid 46032961)
88. Dispenzieri A, Kyle RA, Lacy MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral stem cell transplantation. A case control study. Blood 2004; 103: 2949-2951. (Pubitemid 38596319)
89. Goldsmith YB, Liu J, Chou J et al. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring Am J Cardiol 2009; 104: 990-994.
90. Gertz MA, Lacy MQ, Dispenzieri A et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025-1031.
91. Mhaskar R, Kumar A, Behera M et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant 2009; 15: 893-902.
92. Jaccard A, Moreau P, Leblond V et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093. (Pubitemid 47443213)
93. Leung N, Gunderson H, Tan TS et al. Malphalan and dexamethason is less effective for patients with immunoglobulin light chain amyloidosis with high bone marrow plasmocytosis. Blood 2008; 112: 612. Abstract 1735.
94. Sanchorawala V, Seldin DC, Magnani B et al. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36: 597-600. (Pubitemid 43115014)
95. Madan S, Kumar S, Dispenzieri A et al. Outcomes with high dose therapy and peripheral blood stem cell transplantation for light chain amyloidosis with cardiac involvement. Blood 2009; 114 (Suppl N22): 223. Abstract 534.
96. Landau H, Hassoun H, Cohen AD et al. Adjuvant bortezomib and dexamethasone following risk adapted melphalan and stem cell transplant in systemic light chain amyloidosis. Blood 2009; 114 (Suppl N22): 222. Abstract 533.
97. Landau HJ, Hoffman J, Hassoun H et al. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL). J Clin Oncol 2009; 27: 15. Abstract 8540.
98. Hoffman JE, Hassoun H, Landau H et al. Early adjuvant treatment after risk adapted autologou stem cell transplant for systemic light chain amyloidosis. Increased hospitalization and impaired immune recovery but improved responses and overall survival. Blood 2008; 112: 1143. Abstract 3329.